



Synthesis of some novel 1,2,4-triazole derivatives as potential antimicrobial agents

Mohamed Sayed Behalo *, Aly Abdelmaboud Aly, Ashraf Farouk Wasfy and Marwa Mohamed Rizk

Chemistry Department, Faculty of Science, Benha University, Benha, 13518, Egypt

*Corresponding author at: Chemistry Department, Faculty of Science, Benha University, Benha, 13518, Egypt. Tel.: +2.010.1599607; fax: +2.013.3222578. E-mail address: mohamedbehalo@hotmail.com (M. Behalo).

ARTICLE INFORMATION

Received: 18 April 2012
Received in revised form: 05 June 2012
Accepted: 05 June 2012
Online: 30 June 2013

KEYWORDS

Quinoline
1,2,4-Triazole
Spectroscopy
Antifungal activities
Antibacterial activities
1,2,4-Triazolol[3,4-b]thiadiazole

ABSTRACT

An efficient synthesis of 1,2,4-triazole derivatives, fused to five and six membered rings from 4-amino-5-[(quinolin-8-yloxy)methyl]-4*H*-1,2,4-triazole-3-thiole (**2**) was described. The structural formula of all derivatives was confirmed and characterized by elemental analysis and spectral studies. Some of the synthesized compounds were also investigated for their antibacterial and antifungal activities and compared with standard drugs. Most of the tested compounds demonstrated potent to weak antimicrobial activities.

1. Introduction

The triazole ring is a frequent partner in polycyclic heterocyclic systems of biological significance and industrial applications. Compounds containing a fused 1,2,4-triazole moiety have attracted attention in the past few years owing to their biological activity. A number of these class of compounds act as antibacterial [1-3], antifungal [4-6], anti-inflammatory [7], analgesic [8-10], antituberculosis [11] and anticonvulsant agents [12-14]. In addition, a large number of triazole derivatives have antiulcer [15,16], antidepressant [17,18], insecticidal [19], hypolipidemic [20], antidiabetic [21] and antimutagenic activity [22].

Also, azetidino-2-ones of 3-pyridyl-4-amino-5-mercapto-1,2,4-triazoles [23] and 4-(*N*-pyridylcarboxamido)-5-mercapto-3-substitued 1,2,4-triazoles [24] have been reported to possess significant activity as antitumor and antiviral agents. On the other hand, quinoline derivatives have been proven as privileged core structures and confirmed in bioactive natural products and in various pharmaceutical agents. They are known for their antiparasitic properties and have been used as the starting compounds for new antimalarial agents [25,26].

Prompted by the varied biological activities of triazole derivatives and in continuation of our efforts for the synthesis of biologically active heterocycles [27-29], the present work describes the synthesis of novel 1,2,4-triazole derivatives attached with quinoline moiety with the aim of enhancement of their biological activity.

2. Experimental

2.1. Instrumentation

Melting point of the synthesized compounds was determined in Perkin Elmer apparatus and is uncorrected. IR

spectra were recorded using KBr pellets. ¹H NMR spectra were recorded on Mercury-300BB (NMR 200) in CDCl₃, DMSO-*d*₆ as solvent. Tetramethylsilan (TMS) served as an internal reference and chemical shifts were expressed in δ (ppm). Mass spectra were recorded on GC-MS Shimadzu QP2010. All the microanalysis and antimicrobial activities were performed by the Micro analytical unit, Cairo University.


2.2. Synthesis

2.2.1. 2-(Quinolin-8-yloxy)acetohydrazide (**1**)

The titled compound was prepared according to the method described in the literature [30]. A mixture of hydrazine hydrate (0.01 mol) and ethyl 2-(quinolin-8-yl-oxy)acetate (0.01 mol) in ethanol (30 mL) was heated under reflux for 4 hours. After cooling, the precipitated solid was collected and recrystallized from ethanol. Color: Yellow. Yield: 70%. M.p.: 218-220 °C. FT-IR (KBr, ν, cm⁻¹): 3322-3254 (NH₂, NH), 1661 (C=O), 1611 (C=N). ¹H NMR (200 MHz, CDCl₃, δ, ppm): 9.7 (s, 1H, CONH), 8.9 (s, 2H, NH₂), 7.2-7.5 (m, 6H, Ar-H), 4.9 (s, 2H, OCH₂). MS (EI, *m/z* (%)): 217 (M⁺, 22.54), 186 (54.67), 145 (100), 117 (50.54), 91 (2.25), 64 (5.75). Anal. calcd. for C₁₁H₁₁N₃O: C, 60.82; H, 5.10; N, 19.34. Found: C, 60.80; H, 5.08; N, 19.32%.

2.2.2. 4-Amino-5-[(quinolin-8-yloxy)methyl]-4*H*-1,2,4-triazole-3-thiol (**2**)

Carbon disulfide (0.015 mol) was added drop wise to a solution of hydrazide **1** (0.01 mol) in ethanol (30 mL) and potassium hydroxide (0.015 mol). The mixture was stirred at room temperature for 14 h., dry diethyl ether (20 mL) was added and the separated solid was filtered off and washed with diethyl ether, the potassium salt was used for the next stage without further purification.



Scheme 1

Hydrazine hydrate (0.02 mol) was gradually added to the above potassium salt (0.01 mol) dissolved in water (20 mL) and all were refluxed with stirring for 4h. The reaction mixture was cooled and acidified with conc. HCl. A yellow solid separated out which was filtered, washed with water and purified by recrystallization from ethanol to afford triazole **2** (Scheme 1). Color: Yellow. Yield: 65%. M.p.: 228-230 °C. FT-IR (KBr, ν , cm^{-1}): 3402-3145 (NH₂), 2911 (CH₂), 2668(SH), 1596 (C=N). ¹H NMR (200 MHz, DMSO-*d*₆, δ , ppm): 13.9 (s, 2H, NH₂), 9.1(s, 1H, SH), 7.7-7.9 (m, 6H, Ar-H), 5.4 (s, 2H, OCH₂). MS (EI, m/z (%)): 273 (M⁺, 24.82), 145 (100), 117 (40.77), 91 (2.42), 64 (6.41). Anal. calcd. for C₁₂H₁₁N₅OS: C, 52.73; H, 4.06; N, 25.62. Found: C, 52.68; H, 4.02; N, 25.66%.

2.2.3. General procedure for preparation of 3a-b

A mixture of triazole **2** (0.01 mol) and urea/thiourea (0.015 mol) was fused at 232 °C for 2h. After cooling, the solid was triturated with water and filtered off, washed and crystallized from ethanol.

Alternative method for synthesis of **3b**: A mixture of an equimolar amount of compound **2** and CS₂ (0.02 mol) in DMF (50 mL) was refluxed for 6 h. then it cooled and poured onto ice. The product was filtered off and crystallized from acetic acid (Scheme 1).

3-((Quinolin-8-yloxy)methyl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-6(5H)-one (**3a**): Color: Pale yellow. Yield: 52%. M.p.: 248-250 °C. FT-IR (KBr, ν , cm^{-1}): 3409-3165 (NH), 2917 (CH₂), 1685 (C=O), 1618 (C=N), 1310 cm^{-1} (NCS). ¹H NMR (200 MHz, DMSO-*d*₆, δ , ppm): 13.6 (s, 1H, NH), 8.6-7.2 (m, 6H, Ar-H), 5.1 (s, 2H, OCH₂). MS (EI, m/z (%)): 298 (M⁺, 25.05), 273 (31.69), 257 (46.78), 157 (1.62), 145 (100). Anal. calcd. for C₁₃H₉N₅O₂S: C, 52.17; H, 3.03; N, 23.40. Found: C, 52.07; H, 2.99; N, 23.30%.

3-((Quinolin-8-yloxy)methyl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-6(5H)-thione (**3b**): Color: Yellow. Yield: 55%. M.p.: 218-220 °C. FT-IR (KBr, ν , cm^{-1}): 3406 (NH), 2918 (CH₂), 1622 (C=N), 1375 (NCS), 1279 (C=S). ¹H NMR (200 MHz, DMSO-*d*₆, δ , ppm): 8.8 (s, 1H, NH), 8.2-7.3 (m, 6H, Ar-H), 5.2 (s, 2H, OCH₂). MS (EI, m/z (%)): 315 (M⁺, 15.87), 257 (3.85), 225 (12.50), 184 (3.13), 145 (100). Anal. calcd. for C₁₃H₉N₅OS₂: C, 49.51; H, 2.88; N, 22.21. Found: C, 49.45; H, 2.75; N, 22.15%.

2.2.4. 8-((6-Methyl-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-3-yl)methoxy)quinoline (4)


A mixture of triazole **2** (0.01 mol) and acetyl chloride (0.01 mol) in dry pyridine (25 mL) was heated for 2 h on steam bath. The reaction mixture was poured into crushed ice, the solid product obtained by filtration was purified by crystallization from ethanol (Scheme 1). Color: Yellow. Yield: 58%. M.p.: 203-205 °C. FT-IR (KBr, ν , cm^{-1}): 2921 (CH₂), 1626 (C=N), 1380 (NCS). ¹H NMR (200 MHz, DMSO-*d*₆, δ , ppm): 8.2-7.5 (m, 6H, Ar-H), 5.6 (s, 2H, OCH₂), 2.4 (s, 3H, CH₃). MS (EI, m/z (%)): 299 (M⁺, 12.05), 258 (8.89), 145(100), 56 (0.95). Anal. calcd. for C₁₄H₁₁N₅OS: C, 56.55; H, 3.73; N, 23.55. Found: C, 56.49; H, 3.68; N, 23.50%.

2.2.5. General procedure for preparation of 5a-c

A mixture of triazole **2** (0.01 mol) and aromatic acids namely (*p*-nitrobenzoic acid, *p*-aminobenzoic acid, *p*-hydroxy benzoic acid) (0.01 mol) in the presence of POCl₃ (15 mL) was refluxed for 3 h. After removal of the excess of POCl₃ under reduced pressure, the residue was added to crushed ice and stirred at room temperature for 1 h. during this time the solution was gradually neutralized with Na₂CO₃, the solid product was filtered off, washed with water, dried and crystallized from DMF (Scheme 1).

8-((6-(4-Nitrophenyl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazole-3-yl)methoxy)quinoline (**5a**): Color: Yellow. Yield: 72%. M.p.: 150-152 °C. FT-IR (KBr, ν , cm^{-1}): 2924 (CH₂), 1606 (C=N), 1496 (NO₂), 1344 (NCS). ¹H NMR (200 MHz, DMSO-*d*₆, δ , ppm): 6.5-8.3 (m, 10H, Ar-H), 5.7 (s, 2H, OCH₂). MS (EI, m/z (%)): 404 (M⁺, 85.23), 257 (9.01), 225 (5.08), 145 (100), 117 (50.89), 91 (30.45), 64 (0.05). Anal. calcd. for C₁₉H₁₂N₆O₃S: C, 56.43; H, 2.99; N, 20.78 %. Found: C, 56.35; H, 2.90; N, 20.68 %.

4-(3-((Quinolin-8-yloxy)methyl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-6-yl)aniline (**5b**): Color: Yellow. Yield: 74%. M.p.: 208-210 °C. FT-IR (KBr, ν , cm^{-1}): 3410 (NH₂), 2925 (CH₂), 1600 (C=N), 1316 (NCS). ¹H NMR (200 MHz, DMSO-*d*₆, δ , ppm): 11.9 (s, 2H, NH₂), 6.9-8.2 (m, 10H, Ar-H), 5.2 (s, 2H, OCH₂). MS (EI, m/z (%)): 375 (M⁺, 10.89), 256 (9.10), 145 (20.89), 117 (50.66), 91 (30.78), 64 (100). Anal. calcd. for C₁₉H₁₄N₆OS: C, 60.95; H, 3.77; N, 22.45. Found: C, 60.93; H, 3.75; N, 22.42%.



Scheme 2

4-(3-((Quinolin-8-yloxy)methyl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-6-yl)phenol (**5c**): Color: Yellow. Yield: 66%. M.p.: 233-235 °C. FT-IR (KBr, ν , cm⁻¹): 3387 (OH), 2925 (CH₂), 1598 (C=N), 1377 (NCS). ¹H NMR (200 MHz, DMSO-*d*₆, δ , ppm): 13.8 (s, 1H, OH), 7.4-8.3 (m, 10H, Ar-H), 5.3 (s, 2H, OCH₂). Anal. calcd. for C₁₉H₁₃N₅O₃S: C, 60.79; H, 3.49; N, 18.66. Found: C, 60.75; H, 3.50; N, 18.68%.

2.2.6. General procedure for preparation of 6a,b

Triazole **2** (0.01 mol) was fused with phthalic anhydride or maleic anhydride (0.01 mol) for 3h., the reaction mixture was cooled, triturated with water, the separated solid was filtered, washed with water and crystallized from ethanol (Scheme 2).

2-(3-Mercapto-5-((quinolin-8-yloxy)methyl)-4H-1,2,4-triazol-4-yl)isoindolin-1,3-dione (**6a**): Color: Yellow. Yield: 75%. M.p.: 126-128 °C. FT-IR (KBr, ν , cm⁻¹): 2923 (CH₂), 2660 (SH), 1749, 1649 (C=O), 1598 (C=N). ¹H NMR (200 MHz, DMSO-*d*₆, δ , ppm): 8.8 (s, 1H, SH), 7.8-8.1 (m, 10H, Ar-H), 4.9 (s, 2H, OCH₂). MS (EI, m/z (%)): 403 (M⁺, 2.85). Anal. calcd. for C₂₀H₁₃N₅O₃S: C, 59.55; H, 3.25; N, 17.36. Found: C, 59.50; H, 3.35; N, 17.40 %.


1-(3-Mercapto-5-((quinolin-8-yloxy)methyl)-4H-1,2,4-triazol-4-yl)-1H-pyrrole-2,5-dione (**6b**): Color: Pale yellow. Yield: 73%. M.p.: 143-145 °C. FT-IR (KBr, ν , cm⁻¹): 2922 (CH₂), 2668 (SH), 1706,1680 (C=O), 1597 (C=N). ¹H NMR (200 MHz, DMSO-*d*₆, δ , ppm): 10.1 (s, 1H, SH), 8.6-7.7 (m, 8H, Ar-H), 5.1 (s, 2H, OCH₂). MS (EI, m/z (%)): 355 (M⁺, 4.77), 257 (1.95), 158 (48.25), 145 (100), 117 (9.05), 91 (10.23), 64 (6.59). Anal. calcd. for C₁₆H₁₁N₅O₃S: C, 54.38; H, 3.14; N, 19.82. Found: C, 54.40; H, 3.12; N, 19.89%.

2.2.7. 8-((6-Methyl-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-3-yl)methoxy)quinoline (**7**)

A solution of triazole **2** (0.01 mol) in acetic anhydride (20 mL) was heated under reflux for 14 h, after cooling; the reaction mixture was poured into ice. The obtained solid was crystallized from ethanol (Scheme 2). Color: Yellow. Yield: 57%. M.p.: 200-202 °C. FT-IR (KBr, ν , cm⁻¹): 2921 (CH₂), 1599 (C=N), 1373 (NCS). ¹H NMR (200 MHz, DMSO-*d*₆, δ , ppm): 8.1-7.9 (m, 6H, Ar-H), 4.8 (s, 2H, OCH₂), 2.8 (s, 3H, CH₃). MS (EI, m/z (%)): 299 (M⁺, 20.89), 259 (10.50), 179 (30.89), 92 (8.09), 56 (100). Anal. calcd. for C₁₄H₁₁N₅OS: C, 56.55; H, 3.73; N, 23.55. Found: C, 56.75; H, 3.60; N, 23.45%.

2.2.8. 4-([3-Mercapto-5-(quinolin-8-yloxymethyl)-[1,2,4]triazol-4-ylimino]-methyl)-phenol (**8**)

A solution of triazole **2** (0.01 mol) in glacial acetic acid (10 mL) reacted with *p*-hydroxy benzaldehyde (0.01 mol) under reflux for 1 h, the reaction mixture was then cooled and the precipitated solid was filtered off, washed with water, dried and crystallized from ethanol (Scheme 2). Color: Yellow. Yield: 65%. M.p.: 148-150 °C. FT-IR (KBr, ν , cm⁻¹): 3416 (OH), 2923 (CH₂), 2695 (SH), 1597 (C=N). ¹H NMR (200 MHz, DMSO-*d*₆, δ , ppm): 13.8 (s, 1H, OH), 8.8 (s, 1H, SH), 8.3 (s, 1H, CH=N), 7.4-8.1 (m, 10H, Ar-H), 4.9 (s, 2H, OCH₂). MS (EI, m/z (%)): 379 (M⁺, 36.28). Anal. calcd. for C₁₉H₁₅N₅O₂S: C, 60.46; H, 4.01; N, 18.56. Found: C, 60.55; H, 4.10; N, 18.65%.



Scheme 3

2.2.9. 8-((1,2,4-Triazolo[4,3-d][1,2,3,4]thiazol-6-yl)methoxy)quinoline (9)

A solution of triazole **2** (0.01 mol) in HCl (50 mL) was cooled to 0 °C and a cold solution of sodium nitrite (0.01 mol) in water (10 mL) was gradually added. The reaction mixture was kept at 0-5 °C with stirring for 2h, the mixture was left overnight and diluted with water where upon precipitation took place, the solid that precipitated was collected and crystallized from ethanol (Scheme 2). Color: Yellow. Yield: 50%. M.p.: 128-130 °C. FT-IR (KBr, ν , cm^{-1}): 2920 (CH_2), 1627 ($\text{C}=\text{N}$), 1500 ($\text{N}=\text{N}$), 1385 (NCS). ^1H NMR (200 MHz, $\text{DMSO}-d_6$, δ , ppm): 8.2-7.5 (m, 6H, Ar-H), 5.1 (s, 2H, OCH_2). MS (EI, m/z (%)): 284 (M^+ , 71.33), 257 (1.4), 225 (12.50), 198 (17.48), 184 (3.13), 145 (100), 117 (85.72), 91 (18.54), 64 (61.80). Anal. calcd. for $\text{C}_{12}\text{H}_8\text{N}_6\text{OS}$: C, 50.70; H, 2.84; N, 29.56. Found: C, 50.65; H, 2.75; N, 29.77%.

2.2.10. 3-((Quinolin-8-yloxy)methyl)-5H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazin-6-(7H)-one (10)

To a solution of triazole (0.01 mol) in acetic acid (50 mL), chloroacetic acid (0.01 mol) and fused sodium acetate (0.01 mol) were added. The reaction mixture was refluxed for 6h, the separated solid was filtered and recrystallized from ethanol (Scheme 3). Color: Pale yellow. Yield: 48%. M.p.: 159-161 °C. FT-IR (KBr, ν , cm^{-1}): 3423 (NH), 2922 (CH_2), 1659 ($\text{C}=\text{O}$), 1635 ($\text{C}=\text{N}$), 1390 (NCS). ^1H NMR (200 MHz, $\text{DMSO}-d_6$, δ , ppm): 8.9 (s,

1H, NH), 7.6-8.3 (m, 6H, Ar-H), 5.4 (s, 2H, CH_2), 4.1 (s, 2H, OCH_2). MS (EI, m/z (%)): 313 (M^+ , 3.56). Anal. calcd. for $\text{C}_{14}\text{H}_{11}\text{N}_5\text{O}_2\text{S}$: C, 53.66; H, 3.54; N, 22.35. Found: C, 53.75; H, 3.45; N, 22.29%.

2.2.11. General procedure for preparation of 11a-c

To a mixture of triazole **2** (0.01 mol) and different amino acids namely (anthranilic acid, glycine, and valine) (0.01 mol), POCl_3 was added and the content was heated under reflux for 2h on an oil bath. Excess of POCl_3 was then removed and the residue was poured onto crushed ice and stirred well. These were then washed with NaHCO_3 (5%) and the resulting solids were then, filtered, washed with water and crystallized from DMF (Scheme 3).

2-Methyl-1-[3-(quinolin-8-yloxymethyl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-6-yl]-propylamine (**11a**): Color: Yellow. Yield: 70%. M.p.: 132-135 °C. FT-IR (KBr, ν , cm^{-1}): 3417 (NH_2), 2962 (CH_2), 1656 ($\text{C}=\text{N}$), 1381 (NCS). ^1H NMR (200 MHz, $\text{DMSO}-d_6$, δ , ppm): 10.1 (s, 2H, NH_2), 7.3-8.1 (m, 6H, Ar-H), 5.0 (s, 2H, OCH_2), 2.9 (m, 2H, CH), 1.6 (d, 6H, 2 CH_3). Anal. calcd. for $\text{C}_{17}\text{H}_{18}\text{N}_6\text{OS}$: C, 57.61; H, 5.12; N, 23.71. Found: C, 57.50; H, 4.99; N, 23.80%.

3-((Quinolin-8-yloxy)methyl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-6-yl)methanamine (**11b**): Color: Yellow. Yield: 62%. M.p.: 188-190 °C. FT-IR (KBr, ν , cm^{-1}): 3421 (NH_2), 2926 (CH_2), 1606 ($\text{C}=\text{N}$), 1382 (NCS). ^1H NMR (200 MHz, $\text{DMSO}-d_6$, δ , ppm): 9.9 (s, 2H, NH_2), 7.6-8.3 (m, 6H, Ar-H), 4.7 (s, 2H, OCH_2), 2.9 (s, 2H, CH_2). MS (EI, m/z (%)): 313 (M^+ , 10.25), 160 (0.05), 145

(5.05), 91 (10.09), 64 (100). Anal. calcd. for $C_{14}H_{12}N_6OS$: C, 53.83; H, 3.87; N, 26.91. Found: C, 53.92; H, 3.77; N, 26.82%.

2-[[3-((Quinolin-8-yloxy)methyl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazole-6-yl]benzenamine (11c): Color: Yellow. Yield: 68%. M.p.: 98-100 °C. FT-IR (KBr, ν , cm^{-1}): 3432 (NH₂), 2927 (CH₂), 1611 (C=N), 1376(NCS). ¹H NMR (200 MHz, DMSO-*d*₆, δ , ppm): 8.8 (s, 2H, NH₂), 6.6-8.3 (m, 11H, Ar-H), 5.8 (s, 2H, OCH₂). MS (EI, *m/z* (%)): 374 (M⁺, 4.27), 257 (2.10), 145 (58.72), 117 (100), 91 (18.54), 64 (61.80). Anal. calcd. for $C_{19}H_{14}N_6OS$: C, 60.90; H, 3.77; N, 22.45. Found: C, 60.85; H, 3.65; N, 22.35%.

2.2.12. N-methyl-3-((quinolin-8-yloxy)methyl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-6-amine (12)

An equimolar amount of triazole **2** and methyl isothiocyanate (0.01 mol) in DMF (30 mL) was refluxed for 4h, cooled, and then poured onto ice. The product solid was filtered off and crystallized from ethanol (Scheme 3). Color: Yellow. Yield: 63%. M.p.: 250-252 °C. FT-IR (KBr, ν , cm^{-1}): 3323 (NH), 2845 (CH₂), 1620 (C=N), 1374 (NCS). ¹H NMR (200 MHz, DMSO-*d*₆, δ , ppm): 9.1 (s, 1H, NH), 7.7-8.1 (m, 6H, Ar-H), 4.9 (s, 2H, OCH₂), 2.4 (s, 3H, CH₃). MS (EI, *m/z* (%)): 313 (M⁺, 30.03), 257 (20.43), 184 (0.73), 158 (7.44), 145 (100), 117 (35.78), 64 (5.05). Anal. calcd. for $C_{14}H_{12}N_6OS$: C, 53.83; H, 3.87; N, 26.91. Found: C, 53.75; H, 3.95; N, 26.85%.

2.2.13. N-(3-Mercapto-5-((quinolin-8-yloxy)methyl)-4H-1,2,4-triazol-4-yl) formamide (13)

Triazole **2** (0.01 mol) in formic acid (10 mL) was heated under reflux for 3 h. The solid formed was collected by filtration and crystallized from ethanol (Scheme 3). Color: Yellow. Yield: 60%. M.p.: 254-256 °C. FT-IR (KBr, ν , cm^{-1}): 3410 (NH), 2857 (CH₂), 2729 (SH), 1713 (C=O), 1599 (C=N). ¹H NMR (200 MHz, DMSO-*d*₆, δ , ppm): 12.3 (s, 1H, SH), 9.7 (s, 1H, NH), 8.9 (s, 1H, CHO), 7.2-8.2 (m, 6H, Ar-H), 4.8 (s, 2H, OCH₂). MS (EI, *m/z* (%)): 301 (M⁺, 20.67), 257 (10.78), 145 (100), 117 (45.56), 91 (30.54), 64 (35.89). Anal. calcd. for $C_{13}H_{11}N_5O_2S$: C, 51.82; H, 3.68; N, 23.24. Found: C, 51.99; H, 3.65; N, 23.19%.

2.2.14. 1-[[3-((Quinolin-8-yloxy)methyl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-6-yl]propan-2-one (14)

A mixture of triazole **2** (0.01 mol), ethylacetoacetate (0.02 mol) and triethylamine (0.02 mol) in DMF (20 mL) was heated under reflux for 12 h. The precipitated solid was collected by filtration and crystallized from ethanol (Scheme 3). Color: Yellow. Yield: 60%. M.p. 256-258 °C. FT-IR (KBr, ν , cm^{-1}): 2919 (CH₂), 1679 (C=O), 1599 (C=N), 1379 (NCS). ¹H NMR (200 MHz, DMSO-*d*₆, δ , ppm): 6.9-8.1 (m, 6H, Ar-H), 4.9 (s, 2H, OCH₂), 4.2 (s, 2H, CH₂), 2.3 (s, 3H, CH₃). Anal. calcd. for $C_{16}H_{13}N_5O_2S$: C, 56.63; H, 3.86; N, 20.64. Found: C, 56.55; H, 3.80; N, 20.59%.

2.3. Antimicrobial activity test

The tested microorganisms were Gram-positive bacteria (*Staphylococcus aureus*) and Gram-negative bacteria (*Escherichia coli*). In addition, some fungi (*Candida albicans* and *Aspergillus flavus*) were also tested. On the other hand, Tetracycline and Amphotericin B were used as standard antibacterial and antifungal agents, respectively. The observed data on the antimicrobial activity of the compounds and the standard drugs are given in Table 1.

Agar diffusion method was used for the determination of the preliminary antibacterial and antifungal activity [31] and the results were recorded for each tested compound as the average diameter of inhibition zones (r) of bacterial or fungal growth around the disks in millimeters at 100 μ g concentrations in dimethylsulfoxide.

The Gr(+) test organism and Gr(-) test organism were applied using 8 pore suspension of each test organism separately spreaded over a petri dish containing a solid nutrient agar medium of the following composition (g/L).

Beef extract, 3.0; tryptone, 5.0; Agar, 15.0; and distilled water, 1000.0. After immediately fresh inoculation of the tested organism, a well per each Petri dish was made, and the 0.1 g of the tested compound was filled the 6 mm in diameter well respectively then incubated at 37 °C for 48 h, the diameter of the inhibition zone was measured in mm. Also the antifungal activities were tested using spore suspension of each tested organism separately, spreaded over Petri dish containing solid Czapeks Dox agar of the following composition (g/L).

Sucrose, 30.0; MgSO₄, 0.5; KCl, 0.5; FeSO₄, 0.01; NaNO₃ 3.0; K₂HPO₄ 1.0; Agar, 20.0; and distilled water, 1000.0. After immediately fresh inoculation of the test organism, a 6 mm well per each Petri dish was made, and the tested compounds were added to fill wells respectively, and then incubated at 28 °C for 7 days.

3. Results and discussion

3.1. Synthesis

Scheme 1-3 show the synthetic pathways to prepare the target compounds **2-14**. The starting material 4-amino-5-[[quinolin-8-yloxy] methyl]-4H-1,2,4-triazole-3-thiole (**2**) was synthesized from the reaction of acid hydrazide **1** [30] with carbon disulfide in ethanol containing potassium hydroxide followed by treatment with hydrazine hydrate. The structure of triazole **2** was elucidated by ¹H NMR spectrum that showed signals at δ 13.9 and 10.5 ppm corresponding to NH₂ and SH protons respectively. Also, IR spectrum displays absorption bands at 3263-3145 and 2668 cm^{-1} due to NH₂ and SH absorption (Scheme 1).

Triazole **2** with the reactive amino and thio groups proved to be versatile key precursor for constructing wide range of fused triazole derivatives. Thus, the reactivity of triazole **2** towards variety of chemical reagents with the aim of synthesis of fused heterocyclic systems of expected biological activity was investigated. The reaction of compound **2** with urea or thiourea afforded [1,2,4]-triazolo-[3,4-*b*][1,3,4]-thiadiazoles **3a** and **3b** respectively. Compound **3b** was prepared also from the reaction of 1,2,4-triazole **2** with carbon disulfide in DMF. The structures of the products were assigned on the basis of their spectral data and elemental analysis. Treatment of triazole **2** with acetyl chloride in dry pyridine afforded product **4**. On the other hand, reaction of triazole **2** with aromatic acids namely *p*-nitrobenzoic acid, *p*-aminobenzoic acid and *p*-hydroxy benzoic acid in the presence of POCl₃ gave **5a-c** respectively (Scheme 1).

Furthermore, heating of triazole **2** with acid anhydride namely phthalic anhydride or maleic anhydride afforded triazole derivatives **6a** and **6b** respectively where as refluxing of triazole **2** in acetic anhydride due to ring closure to afford 8-[[6-methyl-[1,2,4]triazolo[3,4-*b*][1,3,4]thiadiazole **7**. However, triazole derivative **8** can be synthesized from reaction of triazole **2** with *p*-hydroxybenzaldehyde in the glacial acetic acid. Treatment of triazole **2** with sodium nitrite gave product **9** (Scheme 2).

Furthermore, the reaction of triazole **2** with chloroacetic acid in the presence of sodium acetate furnished triazolo[3,4-*b*][1,3,4]thiadiazin derivative **10**.

The reactivity of triazole **2** towards amino acids to give triazolo[3,4-*b*][1,3,4]thiadiazole derivatives was investigated. Thus, the reaction of triazole **2** with valine, glycine and anthranilic acid in the presence of POCl₃ due to formation of triazoles **11a-c**, respectively (Scheme 3). The structures of the products were confirmed on the basis of their spectral data.

Table 1. Antimicrobial activities of the synthesized compound *.

Compound No.	<i>Escherichia coli</i>	<i>Staphylococcus aureus</i>	<i>Aspergillus flavus</i>	<i>Candida albicans</i>
3a	-	-	-	-
3b	21	20	-	12
4	14	12	-	12
5a	-	-	-	11
5b	12	11	-	-
5c	13	11	-	12
6a	17	17	12	12
6b	21	20	11	12
7	-	-	-	-
8	14	14	-	13
9	14	12	-	-
10	14	12	-	-
11a	15	13	-	-
11b	13	10	-	-
11c	15	11	-	-
12	15	13	-	13
Tetracycline	24	22	-	-
Amphotericin B	-	-	13	14

* Numbers in table represent the extent of the zone diameter (r, mm) inhibition of either fungal growth or bacterial cells for each compound; (-) no inhibition was observed, i.e. compound not active; (r) > 10 mm, slightly active; (r) > 13 mm, moderately active and (r) > 20 mm, high active.

Reaction of compound **2** with methyl isothiocyanate in the presence of DMF gave heterocycle **12**. On the other hand, heating of triazole **2** with formic acid afforded triazole **13**. When triazole **2** was allowed to react with 1,3-dicarbonyl compounds like ethylacetoacetate, triazole **14** was formed (Scheme 3).

3.2. Antimicrobial activity

1,2,4-Triazole derivatives were reported to have biological activity. In this study, some of the synthesized compounds containing 1,2,4-triazole moiety appear to be promising as potential bio responses which increase their importance towards application in pharmacological, industrial and agriculture fields. Therefore, their effectiveness against a number of microorganisms was tested (Table 1).

The results revealed that majority of the synthesized compounds showed varying degrees of inhibition against the tested microorganisms. In general, the inhibitory activity against the Gram-positive bacteria and Gram-negative bacteria was higher than that of the tested fungi. The tested compounds showed moderate (**6a**, **11** and **12**) to high (**3b** and **6b**) inhibitory effect towards tested bacteria (Table 1). Introduction of thiadiazolethione and pyrrolidindione moiety to triazole ring to give mixed heterocyclic systems **3b** and **6b** enhance antibacterial activities when compared with Tetracycline. It has been observed through the results in Table 1 that **6a** and **6b** derivatives showed both antifungal and antibacterial activities towards the tested organisms. On the other hand, triazoles **8** and **12** showed moderate activity towards the most tested microorganisms, while it is inactive towards *Aspergillus flavus*. In summary, the presence of thiadiazole moiety attached to fused triazole system enhances the inhibition zones of the tested microorganisms.

4. Conclusion

In the present paper, we have described the synthesis of 1,2,4-triazole derivatives fused to five and six membered rings from 4-amino-5-[(quinolin-8-yloxy)methyl]-4H-1,2,4-triazole-3-thiole (**2**). It was observed that some of the synthesized compounds behave as efficient antibacterial and antifungal agents when compared with standard drugs. The structure of all derivatives was confirmed and characterized by elemental analysis and spectroscopic studies.

Acknowledgement

The authors wish to thank Chemistry Department, Faculty of Science, Benha University, Egypt for providing required chemicals to complete this work.

References

1. Karabasanagouda, T.; Adhikari, A. V.; Shetty, N. S. *Eur. J. Med. Chem.* **2007**, *42*, 521-525.
2. Mudasir, R. B.; Abdulrauf, A. *Ind. J. Chem. B* **2009**, *43*, 97-102.
3. Nirmala, K.; Parimala, S. *Ind. J. Heterocycl. Chem.* **2008**, *17*, 331-334.
4. Sztanke, K.; Tuzimski, T.; Rzymowska, J.; Pasternak, K.; Kanadefer, S. *M. Eur. J. Med. Chem.* **2008**, *43(2)*, 404-409.
5. Harendra, S.; Manoj, K. S. *Ind. J. Chem. B* **2001**, *40*, 159-162.
6. Zareef, M.; Iqbal, R.; Mirza, B.; Khalid, M. K.; Manan, A.; Asim, F.; Khan, S.W. *Arkivoc* **2008**, *2*, 141-152.
7. Almasirad, A.; Tabatabai, S. A.; Faizi, M.; Kebria, A.; Mehrabi, N.; Dalavand, A.; Shafiee, A. *Bioorg. Med. Chem.* **2004**, *14*, 6057-6061.
8. Tozkoparan, B.; Kupeli, E.; Yesilada, E.; Isil, S.; Ozalp, M.; Ertan, M. *Arznei. Forschung* **2005**, *55(9)*, 533-538.
9. Shashikant, V. B.; Kailash, G. B.; Aniket, P. S.; Ajit, A.; Chetan, V. K.; Sudarshan, C. D. *Pharmacologyonline* **2008**, *2*, 572-587.
10. Giorgio, R.; Giancarlo, G.; Mario, D. B.; Daniela, P.; Vigilio, B.; Massimiliano, T.; Simona, B.; Elisabetta, B. *Eur. J. Med.* **2008**, *43*, 1665-1680.
11. Menendez, C.; Chollet, A.; Rodriguez, F.; Inard, C.; Pasca, M.; Lherbet, C.; Baltas, M. *Eur. J. Med. Chem.* **2012**, *52*, 275-283.
12. Kucukguzel, I.; Guniz-Kucukguzel, S.; Rollas, S.; Otuk-Sanis, G.; Ozdemir, O.; Bayrak, I.; Altug, T.; Stables, J. *II Farmaco* **2004**, *59(11)*, 893-901.
13. Nadeem, S.; Mash, A.; Waqua, R. A. *Acta Pharm.* **2008**, *58*, 445-454.
14. Jing, C.; Xian-Yu, S.; Kyu-Yun, C.; Jin-Seok, L.; Mi-Sun, S.; Zhe-Shan, Q. B. *Med. Chem.* **2007**, *15*, 6775-6781.
15. Mohamd, A.; Harish, K. *Ind. J. Chem.* **2007**, *46*, 1014-1019.
16. Padmavathi, V.; Sudhakar, G. R.; Padmaja, A.; Kondaiah, P.; Ali, S. *Eur. J. Med.* **2009**, *44*, 2106-2112.
17. Kane, J. M.; Dumble, M. W.; Sorensen, S. M.; Miller, F. P. *J. Med. Chem.* **1988**, *31*, 1253-1255.
18. Athanasia, V.; Theodora, S. P.; Andrew, T.; Anna, T. K.; Alexandra, V. *II Farmaco* **1998**, *53*, 320-326.
19. Bing, C.; Xuhong, Q.; Song, C.; Haidong, L.; Gonghua, S. *Arkivoc* **2003**, *2*, 141-145.
20. Gamal, A. I.; Omar, M. A.; Gamal El-Din, A. A.; Abou-Rahma, M. F.; Radwan, M. *Eur. J. Med.* **2009**, *45*, 1-8.
21. Michael, S. M.; Janet, S.; Michael, M.; Iwan, G.; Brenda, M.; Donald, S. *Eur. J. Med.* **2001**, *36*, 31-42.
22. Ouyang, X.; Piatnitski, E. L.; Pattaropong, V.; Chen, X.; He, H. Y.; Kiselyov, A. S.; Velankar, A.; Kawakami, J.; Labelle, M.; Smith, L.; Lohman, J.; Lee, S. P.; Malikzay, A.; Fleming, J.; Gerlak, J.; Wang, Y.; Rosler, R. L.; Zhou, K.; Mitelman, S.; Camara, M.; Surguladze, D.; Doody, J. F.; Tuma, M. C. *Bioorg. Med. Chem. Lett.* **2006**, *16*, 1191-1196.
23. Priyadarsini, R.; Vijayaraj, T. K.; Ravi, C.; Praba, M. *Ind. J. Heterocycl. Chem.* **2004**, *20*, 165-166.
24. Udupi, R. H.; Bhat, A. R. *Ind. J. Heterocycl. Chem.* **1996**, *6*, 41-45.
25. Dhanabal, T.; Sangeetha, R.; Mohan, P. S. *Tetrahedron* **2006**, *62*, 6258-6262.
26. Arzel, E.; Rocca, P.; Grellier, P.; Labaied, M.; Frappier, F.; Gueritte, F.; Gaspard, C.; Marsais, F.; Godard, A.; Queguiner, G. *J. Med. Chem.* **2001**, *44*, 949-954.
27. Aly, A. A.; Behalo, M. S. *J. Chem. Res.* **2010**, *34(10)*, 571-575.
28. Behalo, M. S.; Aly, A. A. *Eur. J. Chem.* **2011**, *2(3)*, 295-299.
29. Issac, Y. A.; El-Karim, I. G.; Donia, S. G.; Behalo, M. S. *Sulf. Lett.* **2002**, *25(4)*, 183-190.
30. Mohd, A.; Rajesh, A. *Ind. J. Heterocycl. Chem.* **1998**, *7*, 225-228.
31. Leifert, C.; Chidbouree, S.; Hampson, S.; Workman, S.; Sigeo, D.; Epton, H. A. S.; Harbour, A. J. *Appl. Bacteriol.* **1995**, *78*, 97-102.